Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies
Mitochondrial therapeutics have repeatedly fallen short of disease modification, in part because inner-membrane architecture constrains both molecular access and the reversibility of bioenergetic failure. Cardiolipin (CL), the signature phospholipid of the inner mitochondrial membrane, provides a me...
שמור ב:
| Principais autores: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2026-05-01
|
| סדרה: | Frontiers in Physiology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fphys.2026.1813119/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|